Ischemic stroke patients who do not receive intravelous (IV) alteplase, a clot-dissolving medication, are significantly less likely to survive, according to researchers at Georgia State University.
Ischemic stroke is the most common type of stroke. It occurs when a vessel that supplies oxygen-rich blood to the brain becomes blocked, often by a blood clot. IV alteplase was approved by the Food and Drug Administration as a treatment for acute ischemic stroke in 1996 and is known to reduce disability and improve functionality by restoring blood flow to the brain. Yet two decades later, less than 10 percent of patients receive the treatment.
The study, published in the American Journal of Emergency Medicine, analyzed 2008-13 data from the Georgia Coverdell Acute Stroke Registry, and linked it to 2008-13 hospital discharge and 2008-14 death data in Georgia. The investigators found that one year after discharge, acute ischemic stroke patients who did not receive IV alteplase treatment had a 49 percent higher likelihood of death.
"Clinicians may be hesitant to administer IV alteplase because of concerns about the drug's complications, which can include bleeding," said Dr. Moges Ido, the study's lead author and a part-time instructor at Georgia State's School of Public Health. "But this study indicates that unless major contraindications are present, patients should be offered this treatment as a life-saving measure."
The study authors examined data from 9,620 patients who were treated at 48 hospitals. They excluded patients who weren't eligible to receive the treatment because of contraindications, such as a recent history of brain surgery. Only a quarter of the eligible patients received IV alteplase.
Previous randomized studies have shown some long-term mortality reduction for patients treated with IV alteplase but the results were not statistically significant. This study demonstrates that IV alteplase is associated with reduced risk of death, and that eligible patients should be identified and treated swiftly.
Materials provided by Georgia State University. Note: Content may be edited for style and length.
Disclaimer: DoveMed is not responsible for the accuracy of the adapted version of news releases posted to DoveMed by contributing universities and institutions.
References:
Moges S. Ido, Michael R. Frankel, Ike S. Okosun, Richard B. Rothenberg. (2017). The impact of intravenous alteplase on long-term patient survival: The Georgia Coverdell acute stroke registry's experience. The American Journal of Emergency Medicine. DOI: 10.1016/j.ajem.2017.07.092
and connect with fellow professionals
At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.
0 Comments
Please log in to post a comment.